Treatment With the Anti-Diabetic Drug Alogliptin Does Not Increase CV Risk in

Treatment with the anti-diabetic drug alogliptin does not increase CV risk in
… the primary endpoint, which was a composite of cardiovascular death, myocardial infarction, and stroke ," said the chair of the study's steering committee William B. White, MD, from the University of Connecticut School of Medicine in Farmington … Read more on Medical Xpress

Insurance exchange counts down to launch
Rehabilitative and habilitative services and devices: Allows 30 visits per year for either physical therapy, occupational therapy or chiropractor services, 30 visits for speech therapy and 30 visits for cardiac or pulmonary rehab. Laboratory services … Read more on Livingston Daily